A randomized controlled trial of patients with chronic kidney disease (eGFR less than 60 ml/min/1.73m2) to determine if allopurinol 100 mg/day decreased the rate of GFR decline and cardiovascular events.

***(Note: Only registered users can read and contribute to the discussion of this topic). Click here to register.

Time Required (estimated): 30 minutes
Title: Effect of Allopurinol in Chronic Kidney Disease Progression and Cardiovascular Risk
Citation: CJASN 2010, Volume 5, pp. 1388-93
Date Created: 2010
Revisions: None Indicated
Disclaimers: None Indicated
Resource Type: Text
Other: Presented at ECU Nephrology Journal Club by Dr. Lakshmi Turlapati

Recommend to a Colleague/Friend

Was this teaching resource valuable? Scroll down and complete our 6-point Transparent Peer Evaluation.

Click here for the full-text article if you are a registered ECU/PCMH member and are outside the ECU/PCMH campus

***(Note: Additional resources in this topic are recommended by Melanie Hames, DO:

Use of Allopurinol in Slowing the Progression of Renal Disease through its ability to lower serum uric acid level

Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions

Transparent Peer Review
Your reviews are anonymous

[starratingmulti id=”3″]

To learn more about our 6-point transparent peer review system, click here



You must be logged in to post a comment.




Speak your mind

  • Nephrology On-Demand Plus

    Our full-featured iOS app for the iPhone and iPad. NOD + integrates
    1. kidney education,
    2. training, and
    3. recruitment

    into a streamlined and user-friendly interface.


  • Kidney Konnection

    A newsletter that discusses sophisticated topics in Nephrology for physicians in Internal Medicine.
    Click here to access your complimentary subscription